The Translational Drug Discovery Group was recently established as part of a major new strategic investment within the School of Life Sciences. The group comprises medicinal chemistry and molecular pharmacology laboratories and plays a pivotal role in the School’s translational research strategy to create a vibrant collaboration across the chemical, biological and clinical sciences that can translate the fundamental research discoveries within the University into potential new medicines.
Hence, the Translational Drug Discovery Group aims to translate a fundamental understanding of disease processes and molecular targets, whether that knowledge resides within the University of Sussex or in UK-based and international academic and industrial institutions, into novel drugs. The therapeutic areas covered include cancer, neurodegenerative and psychiatric diseases and pathogenic infection. A number of exploratory multi-disciplinary drug discovery programmes have been initiated in partnership with colleagues across the University Schools of Life Sciences and Psychology, the Brighton and Sussex Medical School and the Royal Sussex and Brighton Hospital. Moreover, collaborations with groups outside of the University of Sussex have also commenced.
